Analyzing...
Loading company...
Torrent Pharmaceuticals Ltd. engages in the research, development, manufacture, and marketing of generic pharmaceutical formulations. The company is headquartered in Ahmedabad, Gujarat and currently employs 13,573 full-time employees. The firm is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The firm is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The firm's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The firm's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹13,980 Cr revenue.
COGS 24.2%, employees 19.1%.
“Revenues were INR 3,302 crores up by 14%.”
“India business grew at 12% and Brazil grew at 21%.”
“It used to be twenty four months and today if you file a new dose here, it's going to be thirty six months.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 25.8%▲ | 10.3% |
| ROCE | 9.1%▼ | 13.7% |
| Net Margin | 15.6%▲ | 7.6% |
| EBITDA Margin | 31.5%▲ | 15.4% |
| Debt To Equity | 1.76x▲ | 0.15x |
| Rev Growth 3yr | 12.8%▲ | 10.0% |
| EPS Growth 3yr | 20.2%▲ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹15,723 Cr +36.5% | ₹11,516 Cr +7.3% | ₹10,728 Cr +11.5% | ₹9,620 Cr +13.1% | ₹8,508 Cr +6.3% | ₹8,005 Cr +0.8% | ₹7,939 Cr +3.5% | ₹7,673 Cr |
| Other Income | (₹69 Cr) ↓ Decline | ₹23 Cr -60.3% | ₹58 Cr +28.9% | ₹45 Cr -77.2% | ₹197 Cr +245.6% | ₹57 Cr -53.3% | ₹122 Cr +114.0% | ₹57 Cr |
| Total Income | ₹15,654 Cr +35.7% | ₹11,539 Cr +7.0% | ₹10,786 Cr +11.6% | ₹9,665 Cr +11.0% | ₹8,705 Cr +8.0% | ₹8,062 Cr +0.0% | ₹8,061 Cr +4.3% | ₹7,730 Cr |
| COGS | ₹3,777 Cr +36.1% | ₹2,776 Cr +3.4% | ₹2,686 Cr -1.8% | ₹2,735 Cr +12.0% | ₹2,443 Cr +13.8% | ₹2,147 Cr -0.9% | ₹2,167 Cr -2.3% | ₹2,219 Cr |
| ₹12,677 Cr +43.4% | ₹8,842 Cr +3.8% | ₹8,522 Cr +9.0% | ₹7,818 Cr +11.8% | ₹6,994 Cr +7.0% | ₹6,536 Cr -4.9% | ₹6,874 Cr +0.9% | ₹6,811 Cr | |
| Profit Before Tax | ₹2,867 Cr +7.3% | ₹2,673 Cr +13.6% | ₹2,352 Cr +27.3% | ₹1,847 Cr +50.7% | ₹1,226 Cr -19.7% | ₹1,526 Cr +28.6% | ₹1,187 Cr +111.2% | ₹562 Cr |
| Exceptional Items | (₹110 Cr) -358.3% | (₹24 Cr) ↓ Decline | ₹88 Cr | ₹0.00 Cr +100.0% | (₹485 Cr) | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹357 Cr) |
| ₹711 Cr -6.7% | ₹762 Cr +9.5% | ₹696 Cr +15.6% | ₹602 Cr +34.1% | ₹449 Cr +63.9% | ₹274 Cr +69.1% | ₹162 Cr +28.6% | ₹126 Cr | |
| Net Profit | ₹2,156 Cr +12.8% | ₹1,911 Cr +15.4% | ₹1,656 Cr +33.0% | ₹1,245 Cr +60.2% | ₹777 Cr -37.9% | ₹1,252 Cr +22.1% | ₹1,025 Cr +135.1% | ₹436 Cr |
| Profit (Owners) | ₹2,181 Cr +14.1% | ₹1,911 Cr +15.4% | ₹1,656 Cr +33.0% | ₹1,245 Cr +60.2% | ₹777 Cr -37.9% | ₹1,252 Cr +22.1% | ₹1,025 Cr +135.1% | ₹436 Cr |
| Minority Interest | (₹25 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | (₹99 Cr) -6.5% | (₹93 Cr) ↓ Decline | ₹17 Cr ↑ Recovery | (₹137 Cr) ↓ Decline | ₹12 Cr -88.0% | ₹100 Cr ↑ Recovery | (₹192 Cr) ↓ Decline | ₹33 Cr |
| EPS | ₹64.43 | ₹56.46 | ₹48.93 | ₹36.79 | ₹22.96 | ₹36.99 | ₹30.29 | ₹12.88 |
| Diluted Shares | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Torrent Pharmaceuticals Limited has informed the Exchange about Link of Recording
Torrent Pharmaceuticals Limited has informed the Exchange about change in Management
Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 30, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also encl...
Unaudited Financial Results for quarter ended 30-Jun-26
Torrent Pharmaceuticals Limited has informed the Exchange regarding Appointment of Shanti Ekambaram as Independent Director of the company w.e.f. July 30, 2026.
Torrent Pharmaceuticals Limited has informed the Exchange about General Updates
Torrent Pharmaceuticals Limited has informed the Exchange about General Updates - Allotment of 4,19,22,416 fully paid-up Equity shares of the Company to the eligible shareholders of J. B. Chemicals & ...
Torrent Pharmaceuticals Limited has informed the Exchange about General Updates
Torrent Pharmaceuticals Limited has informed the Exchange about General Updates
Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Torrent Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
Torrent Pharmaceuticals Limited has informed the Exchange about General Updates
Torrent Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of OT is 17-Jul-2026.
Torrent Pharmaceuticals Limited has informed the Exchange about General Updates